123 related articles for article (PubMed ID: 29802645)
1. Trilobatin as an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope.
Yin S; Zhang X; Lai F; Liang T; Wen J; Lin W; Qiu J; Liu S; Li L
FEBS Lett; 2018 Jul; 592(13):2361-2377. PubMed ID: 29802645
[TBL] [Abstract][Full Text] [Related]
2. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S
Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
Li W; Lu L; Li W; Jiang S
Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
[TBL] [Abstract][Full Text] [Related]
4. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
5. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41.
Liu S; Lu H; Zhao Q; He Y; Niu J; Debnath AK; Wu S; Jiang S
Biochim Biophys Acta; 2005 May; 1723(1-3):270-81. PubMed ID: 15823507
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
Yi HA; Fochtman BC; Rizzo RC; Jacobs A
Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target.
Qiu Z; Chong H; Yao X; Su Y; Cui S; He Y
AIDS; 2015 Jun; 29(9):1015-24. PubMed ID: 26125136
[TBL] [Abstract][Full Text] [Related]
8. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
Liu Y; Ke Z; Wu KY; Liu S; Chen WH; Jiang S; Jiang ZH
ChemMedChem; 2011 Sep; 6(9):1654-64. PubMed ID: 21688394
[TBL] [Abstract][Full Text] [Related]
9. Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41.
Hrin R; Montgomery DL; Wang F; Condra JH; An Z; Strohl WR; Bianchi E; Pessi A; Joyce JG; Wang YJ
AIDS Res Hum Retroviruses; 2008 Dec; 24(12):1537-44. PubMed ID: 19102685
[TBL] [Abstract][Full Text] [Related]
10. A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin.
Wensel D; Sun Y; Davis J; Li Z; Zhang S; McDonagh T; Fabrizio D; Cockett M; Krystal M
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743355
[TBL] [Abstract][Full Text] [Related]
11. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
[TBL] [Abstract][Full Text] [Related]
12. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
13. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
14. A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection.
Yang J; Li L; Tan S; Jin H; Qiu J; Mao Q; Li R; Xia C; Jiang ZH; Jiang S; Liu S
Fitoterapia; 2012 Mar; 83(2):348-55. PubMed ID: 22155187
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Pan C; Liu S; Jiang S
J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
[TBL] [Abstract][Full Text] [Related]
16. A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region.
Wang C; Wang X; Wang H; Pu J; Li Q; Li J; Liu Y; Lu L; Jiang S
J Med Chem; 2021 Aug; 64(15):11460-11471. PubMed ID: 34261320
[TBL] [Abstract][Full Text] [Related]
17. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug.
Teixeira C; Gomes JR; Gomes P; Maurel F; Barbault F
Eur J Med Chem; 2011 Apr; 46(4):979-92. PubMed ID: 21345545
[TBL] [Abstract][Full Text] [Related]
18. Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry.
Francis JN; Redman JS; Eckert DM; Kay MS
Bioconjug Chem; 2012 Jun; 23(6):1252-8. PubMed ID: 22545664
[TBL] [Abstract][Full Text] [Related]
19. DNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity.
Xu L; Zhang T; Xu X; Chong H; Lai W; Jiang X; Wang C; He Y; Liu K
Nucleic Acid Ther; 2015 Aug; 25(4):219-25. PubMed ID: 26192705
[TBL] [Abstract][Full Text] [Related]
20. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
